Results 121 to 130 of about 25,234 (166)
Some of the next articles are maybe not open access.
Biochemical Pharmacology, 2016
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire +2 more sources
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire +2 more sources
[SGLT2 inhibitors : only beneficial ?]
Revue medicale suisse, 2021SGLT2 inhibitors are more and more prescribed in the treatment of type 2 diabetes. Their cardioprotective and nephroprotective effects make them particularly attractive. However, it is important to be aware of their potential side effects. This article aims to summarize the actual evidence regarding the most studied ones.
Lucie, Sciotto, Francois R, Jornayvaz
openaire +2 more sources
Abstract SGLT2 inhibitors were first introduced for heart failure in 2020 and are now first-line agents for all patients with symptomatic heart failure regardless of left ventricular ejection fraction. They reduce both morbidity and mortality in clinical trials with an average relative risk reduction of 23% for heart failure ...
Roy S. Gardner +3 more
openaire +2 more sources
Roy S. Gardner +3 more
openaire +2 more sources
Current Opinion in Cardiology, 2018
To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM.
Erika, Opingari +3 more
openaire +2 more sources
To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM.
Erika, Opingari +3 more
openaire +2 more sources
Journal of the American College of Cardiology, 2021
Richard K. Cheng +5 more
openaire +2 more sources
Richard K. Cheng +5 more
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2016
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
Gliflozin (
AbstractIntroductionSodium‐glucose co‐transporter 2 (SGLT2) inhibitors, or gliflozins, are used as mono or combined therapy in the management of diabetes. Genital infections are the most common reported adverse effect, as a result of induced glycosuria.
Stephen J. Mounsey +3 more
openaire +2 more sources
SGLT2 Inhibitors: Benefit/Risk Balance
Current Diabetes Reports, 2016Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycemia by increasing urinary glucose excretion. They have been evaluated in patients with type 2 diabetes treated with diet/exercise, metformin, dual oral therapy or insulin. Three agents are available in Europe and the USA (canagliflozin, dapagliflozin, empagliflozin) and others ...
openaire +2 more sources
SGLT2 inhibitors: new reports.
The Medical letter on drugs and therapeutics, 2016A significant decrease in cardiovascular mortality has been reported with use of the SGLT2 inhibitor empagliflozin (Jardiance) to treat patients with type 2 diabetes who have established cardiovascular disease. The mechanism of this reduction is unclear, and these results may not apply to patients with type 2 diabetes and less advanced cardiovascular ...
openaire +2 more sources
SGLT2 Inhibitors in Diabetes Mellitus Treatment
Reviews on Recent Clinical Trials, 2017Type 2 Diabetes Mellitus (T2DM) is a chronic illness with high prevalence in Mexico, Latin- America, and the world and is associated to high morbidity, disability, and mortality rate, especially in developing countries. T2DM physiopathology is very complex; insulin resistance in the muscle, liver, and adipose tissue, a reduction in the production of ...
Juan, Rosas-Guzman +2 more
openaire +2 more sources